WTX-124 Shows Activity in Solid Tumors
A phase 1/1b study tested the tumor-activated IL-2 prodrug WTX-124 alone and with pembrolizumab in immune-sensitive solid tumors.
Updated on Nov. 8, 2026 in Cancer
Justin Moser presented phase 1/1b study findings on WTX-124, a conditionally activated IL-2 designed to release the cytokine selectively in the tumor microenvironment. The data were presented at the 2026 SITC Annual Meeting.
Why it matters
WTX-124 is designed to avoid the systemic toxicities, including vascular leak syndrome, that have limited high-dose IL-2 use. If the approach holds, it could extend IL-2-based treatment to older patients and a broader range of immune-sensitive tumors.
The phase 1/1b open-label, multicenter study administered WTX-124 intravenously every 2 weeks, alone or with pembrolizumab, and the most common grade 3 or higher toxicities were arthralgia and decreased lymphocyte counts. Response rates and longer-term durability were not reported in the source data.
The players
Justin Moser
Justin Moser presented the phase 1/1b findings and is affiliated with HonorHealth Research Institute.
The details
WTX-124 is a tumor-activated IL-2 prodrug that remains inactive in circulation and releases IL-2 selectively in the tumor microenvironment. Responses were observed in cutaneous melanoma, gastroesophageal cancer, and non-small cell lung cancer, and several patients in their 90s were treated.
Timeline
2026: Data presented at the SITC Annual Meeting
Roadmap
Conventional high-dose IL-2 therapy has been limited by systemic toxicities such as vascular leak syndrome. WTX-124 represents an effort to preserve IL-2's immune-stimulating effect while restricting its activity to the tumor site.
WTX-124 is still in early clinical testing, so it is not yet available as a treatment option. Patients considering immunotherapy should discuss current approved options and trial eligibility with their oncology team.
The takeaway
Early-phase data suggest a tumor-targeted approach to IL-2 may reduce the systemic toxicity that has limited older forms of this therapy. Larger studies will be needed to confirm safety and benefit.
Further reading
Explore more on Cancer treatment research and emerging immunotherapy approaches.
Source note: This article includes information reported by OncLive.
